Abstract
Twenty-four newly diagnosed and previously untreated infantile spasm patients were treated for 3 weeks with either methysergide (12 patients) or alpha-methylparatyrosine (12 patients). Response to therapy was determined objectively with 24-h polygraphic/video monitoring techniques and was defined as cessation of spasms and disappearance of the hypsarrhythmic EEG pattern. Two (17%) of the patients treated with alpha-methylparatyrosine responded to therapy, and one (8%) of the methysergide-treated group showed a response.
Publication types
-
Clinical Trial
-
Controlled Clinical Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adrenocorticotropic Hormone / therapeutic use
-
Barbiturates / therapeutic use
-
Child Development
-
Electroencephalography
-
Humans
-
Infant
-
Methyltyrosines / administration & dosage
-
Methyltyrosines / therapeutic use*
-
Methysergide / administration & dosage
-
Methysergide / therapeutic use*
-
Phenytoin / therapeutic use
-
Random Allocation
-
Recurrence
-
Spasms, Infantile / drug therapy*
-
Spasms, Infantile / physiopathology
-
Tyrosine 3-Monooxygenase / antagonists & inhibitors*
-
alpha-Methyltyrosine
Substances
-
Barbiturates
-
Methyltyrosines
-
Phenytoin
-
alpha-Methyltyrosine
-
Adrenocorticotropic Hormone
-
Tyrosine 3-Monooxygenase
-
Methysergide